Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation

Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. There is a paucity of treatment trials for dementia in Down syndrome in comparison to Alzheimer disease in the general (non‐Down syndrome) population. This 2‐year randomized, double‐blind, placebo‐controlled trial assessed whether daily oral antioxidant supplementation (900 IU of alpha‐tocopherol, 200 mg of ascorbic acid and 600 mg of alpha‐lipoic acid) was effective, safe and tolerable for 53 individuals with Down syndrome and dementia. The outcome measures comprised a battery of neuropsychological assessments administered at baseline and every 6 months. Compared to the placebo group, those individuals receiving the antioxidant supplement showed neither an improvement in cognitive functioning nor a stabilization of cognitive decline. Mean plasma levels of alpha‐tocopherol increased ∼2‐fold in the treatment group and were consistently higher than the placebo group over the treatment period. Pill counts indicated good compliance with the regimen. No serious adverse events attributed to the treatment were noted. We conclude that antioxidant supplementation is safe, though ineffective as a treatment for dementia in individuals with Down syndrome and Alzheimer type dementia. Our findings are similar to studies of antioxidant supplementation in Alzheimer disease in the general population. The feasibility of carrying out a clinical trial for dementia in Down syndrome is demonstrated. © 2011 Wiley‐Liss, Inc.

[1]  J. Rusted,et al.  Vitamin E for Alzheimer's dementia and mild cognitive impairment. , 2012, The Cochrane database of systematic reviews.

[2]  Luca Tiano,et al.  Effect of Coenzyme Q10 in mitigating oxidative DNA damage in Down syndrome patients, a double blind randomized controlled trial , 2011, Neurobiology of Aging.

[3]  C. Cotman,et al.  Synergistic Effects of Long-Term Antioxidant Diet and Behavioral Enrichment on β-Amyloid Load and Non-Amyloidogenic Processing in Aged Canines , 2010, The Journal of Neuroscience.

[4]  Hyoung-Gon Lee,et al.  Antioxidant approaches for the treatment of Alzheimer’s disease , 2010, Expert Review of Neurotherapeutics.

[5]  C. Cotman,et al.  Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. , 2010, Journal of Alzheimer's disease : JAD.

[6]  Mara Dierssen,et al.  Cognitive deficits and associated neurological complications in individuals with Down's syndrome , 2010, The Lancet Neurology.

[7]  K. Yamakawa,et al.  Enlarged brain ventricles and impaired neurogenesis in the Ts1Cje and Ts2Cje mouse models of Down syndrome. , 2010, Cerebral cortex.

[8]  B. Vellas,et al.  Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer’s disease , 2010, CNS drugs.

[9]  R. Petersen,et al.  NIA-Funded Alzheimer Centers Are More Efficient than Commercial Clinical Recruitment Sites for Conducting Secondary Prevention Trials of Dementia , 2010, Alzheimer disease and associated disorders.

[10]  K. Gardiner Molecular basis of pharmacotherapies for cognition in Down syndrome. , 2010, Trends in pharmacological sciences.

[11]  M. Rethoré,et al.  Effect of Leucovorin (Folinic Acid) on the Developmental Quotient of Children with Down's Syndrome (Trisomy 21) and Influence of Thyroid Status , 2010, PloS one.

[12]  A case for cautious optimism , 2010, Nature Neuroscience.

[13]  Donna K Slonim,et al.  Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses , 2009, Proceedings of the National Academy of Sciences.

[14]  D. Schade,et al.  The response of gamma vitamin E to varying dosages of alpha vitamin E plus vitamin C. , 2009, Metabolism: clinical and experimental.

[15]  A. Granholm,et al.  Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model , 2009, Experimental Neurology.

[16]  D. Praticò,et al.  Oxidative stress and cognitive ability in adults with Down syndrome , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[17]  G. Perry,et al.  Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease , 2009, Free radical research.

[18]  A. Dalton The Dyspraxia Scale for adults with Down syndrome , 2009 .

[19]  F. Pallardó,et al.  Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. , 2009, Journal of Alzheimer's disease : JAD.

[20]  Elizabeth Head,et al.  Strategies for improving cognition with aging: insights from a longitudinal study of antioxidant and behavioral enrichment in canines , 2009, AGE.

[21]  P. Whitaker-Azmitia,et al.  Vitamin E increases S100B‐mediated microglial activation in an S100B‐overexpressing mouse model of pathological aging , 2008, Glia.

[22]  Ricardo Aurino Pinho,et al.  The exercise redox paradigm in the Down’s syndrome: improvements in motor function and increases in blood oxidative status in young adults , 2008, Journal of Neural Transmission.

[23]  M. Altamirano-Lozano,et al.  High Dosage of Ascorbic Acid and Alpha-Tocopherol Is Not Useful for Diminishing Oxidative Stress and DNA Damage in Healthy Elderly Adults , 2008, Annals of Nutrition and Metabolism.

[24]  S. Leonard,et al.  Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. , 2008, Free radical biology & medicine.

[25]  W. Henley,et al.  Supplementation with antioxidants and folinic acid for children with Down’s syndrome: randomised controlled trial , 2008, BMJ : British Medical Journal.

[26]  P. Crane,et al.  Antioxidant Vitamin Supplement Use and Risk of Dementia or Alzheimer's Disease in Older Adults , 2008, Journal of the American Geriatrics Society.

[27]  Carl W. Cotman,et al.  Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer's disease , 2008, Neurobiology of Aging.

[28]  G. Fiskum,et al.  Mitochondrial dysfunction in mouse trisomy 16 brain , 2008, Brain Research.

[29]  R. Bartesaghi,et al.  RESEARCH ARTICLE: Neurogenesis Impairment and Increased Cell Death Reduce Total Neuron Number in the Hippocampal Region of Fetuses with Down Syndrome , 2007, Brain pathology.

[30]  Elizabeth Head,et al.  The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. , 2008, Journal of Alzheimer's disease : JAD.

[31]  N. Tabet,et al.  Vitamin E for Alzheimer's disease and mild cognitive impairment. , 2008, The Cochrane database of systematic reviews.

[32]  M. Schapiro,et al.  Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. , 2007, Pediatric neurology.

[33]  A. Hassiotis,et al.  Prevalence of dementia in intellectual disability using different diagnostic criteria. , 2007, The British journal of psychiatry : the journal of mental science.

[34]  A. Cossarizza,et al.  Mitochondrial alterations and tendency to apoptosis in peripheral blood cells from children with Down syndrome , 2007, FEBS letters.

[35]  G. Münch,et al.  α-Lipoic acid as a new treatment option for Alzheimer’s disease — a 48 months follow-up analysis , 2007 .

[36]  I. Lott,et al.  Alzheimer's disease in Down syndrome: neurobiology and risk. , 2007, Mental retardation and developmental disabilities research reviews.

[37]  G. Münch,et al.  Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. , 2007, Journal of neural transmission. Supplementum.

[38]  Nancy Cook,et al.  A randomized trial of vitamin E supplementation and cognitive function in women. , 2006, Archives of internal medicine.

[39]  P. Eikelenboom,et al.  Dementia and mortality in persons with Down's syndrome. , 2006, Journal of intellectual disability research : JIDR.

[40]  D. Allan Butterfield,et al.  Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer's disease , 2006, Neurobiology of Disease.

[41]  T. Montine,et al.  Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. , 2006, Free radical biology & medicine.

[42]  W. Markesbery,et al.  Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment , 2006, Journal of neurochemistry.

[43]  J. Hanlon,et al.  Dementia and Alzheimer's Disease in Community-Dwelling Elders Taking Vitamin C and/or Vitamin E , 2005, The Annals of pharmacotherapy.

[44]  T. Shea,et al.  Folate, vitamin E, and acetyl-l-carnitine provide synergistic protection against oxidative stress resulting from exposure of human neuroblastoma cells to amyloid-beta , 2005, Brain Research.

[45]  D. Patel,et al.  Complementary and alternative medicine in developmental disabilities , 2005, Indian journal of pediatrics.

[46]  W. Markesbery,et al.  Ribosome Dysfunction Is an Early Event in Alzheimer's Disease , 2005, The Journal of Neuroscience.

[47]  D. Bennett,et al.  Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.

[48]  W. Tsai,et al.  Assessment of Aging Individuals with Down Syndrome in Clinical Trials: Results of Baseline Measures , 2005 .

[49]  C. Maxwell,et al.  Supplemental Use of Antioxidant Vitamins and Subsequent Risk of Cognitive Decline and Dementia , 2005, Dementia and Geriatric Cognitive Disorders.

[50]  E. Wolvetang,et al.  ets-2 Promotes the Activation of a Mitochondrial Death Pathway in Down's Syndrome Neurons , 2005, The Journal of Neuroscience.

[51]  C. Cotman,et al.  Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study , 2004, Neurobiology of Aging.

[52]  R. Stocker,et al.  Vitamin E in human low-density lipoprotein , 2005 .

[53]  K. Yaffe,et al.  Impact of antioxidants, zinc, and copper on cognition in the elderly , 2004, Neurology.

[54]  P. Mecocci,et al.  Plasma Antioxidant Status, Immunoglobulin G Oxidation and Lipid Peroxidation in Demented Patients: Relevance to Alzheimer Disease and Vascular Dementia , 2004, Dementia and Geriatric Cognitive Disorders.

[55]  S. S. Levinson,et al.  Vitamins in human arteriosclerosis with emphasis on vitamin C and vitamin E. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[56]  D. Tappa,et al.  Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification : a two-year longitudinal study , 2004 .

[57]  L. Appel,et al.  Supplementation of Diets with α-Tocopherol Reduces Serum Concentrations of γ- and δ-Tocopherol in Humans , 2003 .

[58]  R. Mayeux,et al.  Antioxidant vitamin intake and risk of Alzheimer disease. , 2003, Archives of neurology.

[59]  L. Appel,et al.  Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. , 2003, The Journal of nutrition.

[60]  C. Cotman,et al.  β-Amyloid deposition and neurofibrillary tangle association with caspase activation in Down syndrome , 2002, Neuroscience Letters.

[61]  C. Cotman,et al.  Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction , 2002, Neurobiology of Aging.

[62]  Denis A. Evans,et al.  Vitamin E and cognitive decline in older persons. , 2002, Archives of neurology.

[63]  A. Hofman,et al.  Dietary Intake of Antioxidants and Risk of Alzheimer Disease , 2002 .

[64]  B. Lawlor,et al.  Dementia in people with Down's syndrome , 2001, International journal of geriatric psychiatry.

[65]  A. Reiss,et al.  Neuroanatomy of Down's syndrome: a high-resolution MRI study. , 2001, The American journal of psychiatry.

[66]  W. Markesbery,et al.  Oxidative Alterations in Alzheimer's Disease , 1999, Brain pathology.

[67]  J. Andersen,et al.  Stress, Aging, and Neurodegenerative Disorders: Molecular Mechanisms a , 1998, Annals of the New York Academy of Sciences.

[68]  M. Smith,et al.  Early glycoxidation damage in brains from Down's syndrome. , 1998, Biochemical and biophysical research communications.

[69]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[70]  R. Stocker,et al.  Requirement for, promotion, or inhibition by alpha-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. , 1997, Free radical biology & medicine.

[71]  C. Goetz,et al.  Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients , 1996, Neurology.

[72]  H. Evenhuis,et al.  Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR). , 1996, Journal of intellectual disability research : JIDR.

[73]  R. Bucks,et al.  Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. , 1996, Age and ageing.

[74]  R. Dean,et al.  Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[75]  J. Cleary,et al.  Prevention of Tocopherol-mediated Peroxidation in Ubiquinol-10-free Human Low Density Lipoprotein (*) , 1995, The Journal of Biological Chemistry.

[76]  N. Driesen,et al.  Selective neuroanatornic abnormalities in Down's syndrome and their cognitive correlates , 1995, Neurology.

[77]  F. Boller,et al.  Severe impairment battery. A neuropsychological test for severely demented patients. , 1994, Archives of neurology.

[78]  H. Evenhuis,et al.  Evaluation of a screening instrument for dementia in ageing mentally retarded persons. , 2008, Journal of intellectual disability research : JIDR.

[79]  R. Stocker,et al.  Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. , 1992, The Biochemical journal.

[80]  B. Frei Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. , 1991, The American journal of clinical nutrition.

[81]  E. Niki,et al.  Action of ascorbic acid as a scavenger of active and stable oxygen radicals. , 1991, The American journal of clinical nutrition.

[82]  R. Bonfanti,et al.  Simultaneous determination of retinol, tocopherols, carotenes and lycopene in plasma by means of high-performance liquid chromatography on reversed phase. , 1991, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[83]  G. Bartosz,et al.  Down's syndrome: a pathology involving the lack of balance of reactive oxygen species. , 1988, Free radical biology & medicine.

[84]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[85]  J. Weiter,et al.  Oral α-Tocopherol Supplements Decrease Plasma γ-Tocopherol Levels in Humans , 1985 .

[86]  J. Weiter,et al.  Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. , 1985, The Journal of nutrition.

[87]  S. Sparrow,et al.  The behavior inventory for rating development (BIRD): assessments of reliability and factorial validity. , 1984, Applied research in mental retardation.

[88]  K. Kojima Proceedings of the fifth Berkeley symposium on mathematical statistics and probability. , 1969 .

[89]  H. L. Le Roy,et al.  Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; Vol. IV , 1969 .

[90]  P. J. Huber The behavior of maximum likelihood estimates under nonstandard conditions , 1967 .